Formulation and stability design spaces for a new yellow fever vaccine
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2026.115177 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Didier Clénet und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Bioprocess Development, Vaccine CMC Development & Supply, Sanofi, Marcy l'Etoile, France. Electronic address: didier.clenet@sanofi.com. Hauptthemen laut MEDLINE: Yellow Fever Vaccine, Yellow Fever. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi Pasteur SA.
Abstract (Originalsprache)
Yellow fever (YF) is a life-threatening disease that is entirely preventable through vaccination. The objective of this study was to formulate a freeze-dried presentation of a live-attenuated, Vero cell-based yellow fever vaccine (vYF) with improved manufacturability and enhanced shelf-life. Considering four critical quality attributes (i.e., glass transition temperatures and infectious titers at two time points), a comprehensive formulation screening was performed to identify an optimal combination of excipients, capable of protecting the virus during lyophilization while ensuring long-term stability of the vYF infectious titer. Overall, L-proline, urea, and poloxamer 407 demonstrated a stabilizing effect, and the application of an advanced kinetic model enabled prediction of a 60-month shelf-life at 5 °C for the formulated vaccine. Machine learning models were used to build both formulation and stability design spaces that defined global stabilizing regions within the explored concentration ranges of each excipient. This study demonstrates that the combination of systematic excipient screening and advanced analytics enables the selection of robust formulations with long-term stability within an accelerated development timeframe. The developed vaccine formulation has the potential for large-scale industrial production and can address substantial market demand in the coming years, representing a significant advancement in vYF technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Bioprocess Development, Vaccine CMC Development & Supply, Sanofi, Marcy l'Etoile, France. Electronic address: didier.clenet@sanofi.com.
- Center of Excellence, Capgemini Engineering, Lyon, France.
- Global Bioprocess Development, Vaccine CMC Development & Supply, Sanofi, Marcy l'Etoile, France.
- Global CMC Leadership, Sanofi, Marcy l'Etoile, France.
- R&D Global Projects Strategy and Execution, Sanofi, Marcy l'Etoile, France.
Förderung
- Sanofi Pasteur SA
Zitieren
APA
Clénet, D., Mansois, N., Guo, Y., Dos Ramos, B. A., Bertaux, L., & Vangelisti, M. (2026). Formulation and stability design spaces for a new yellow fever vaccine. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115177
Vancouver
Clénet D, Mansois N, Guo Y, Dos Ramos BA, Bertaux L, Vangelisti M. Formulation and stability design spaces for a new yellow fever vaccine. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115177
BibTeX
@article{Clnet2026,
author = {Clénet, Didier and Mansois, Noémie and Guo, Yawen and Dos Ramos, Bruna Araujo and Bertaux, Landry and Vangelisti, Manuel},
title = {Formulation and stability design spaces for a new yellow fever vaccine},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2026.115177}
}
EUVIMED